title: Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations.
abstract: The molecular events that give rise to ovarian epithelial neoplasms are not well understood. In particular, it is not known whether adenocarcinomas arise from benign or low malignant potential (LMP) precursors. We have examined a large series of benign (25) and LMP (31) ovarian tumors for loss of heterozygosity (LOH) at multiple loci on 17 chromosomes. LOH was observed in benign tumors on chromosomes 6 (14%) and 9 (5%) and on the X chromosome (33%) only. LOH on these chromosomes was also detected in a small number of LMP neoplasms, suggesting that these may derive sometimes from benign precursors. In addition, we examined LOH in 93 adenocarcinomas. Analysis of associations between LOH events showed that LOH on chromosomes 5 and 17 (P = 0.0002) and on chromosomes 17 and 18 (P = 0.00007) were associated significantly with each other, which suggests that these may represent cooperative, progressive events. No novel significant associations were identified between LOH events and stage, grade, or histology, which would indicate the existence of genetic heterogeneity in ovarian neoplasms. KRAS2 mutations were detected more often in LMP neoplasms than in malignant tumors (P = 0.004) and were detected more often in Stage I/II malignant tumors than in Stage III/IV malignant tumors (P = 0.033), suggesting that LMP tumors with KRAS2 mutations are unlikely to progress to frank malignancy. Univariate (but not multivariate) survival analysis showed that LOH of chromosomes 11 (P = 0.039) and 17 (P = 0.04) was associated with a significantly worse prognosis. Replication of these novel findings is necessary, and the identification, isolation, and characterization of the critical genes affected by LOH will determine their importance in the pathogenesis of ovarian malignancies.
authors.affiliation: Queensland Institute of Medical Research, Brisbane, Australia.
authors.forename: G
authors.initials: G
authors.lastname: Chenevix-Trench
authors.forename: J
authors.initials: J
authors.lastname: Kerr
authors.forename: T
authors.initials: T
authors.lastname: Hurst
authors.forename: Y C
authors.initials: YC
authors.lastname: Shih
authors.forename: D
authors.initials: D
authors.lastname: Purdie
authors.forename: L
authors.initials: L
authors.lastname: Bergman
authors.forename: M
authors.initials: M
authors.lastname: Friedlander
authors.forename: B
authors.initials: B
authors.lastname: Sanderson
authors.forename: A
authors.initials: A
authors.lastname: Zournazi
authors.forename: T
authors.initials: T
authors.lastname: Coombs
authors.forename: J A
authors.initials: JA
authors.lastname: Leary
authors.forename: E
authors.initials: E
authors.lastname: Crawford
authors.forename: A N
authors.initials: AN
authors.lastname: Shelling
authors.forename: I
authors.initials: I
authors.lastname: Cooke
authors.forename: T S
authors.initials: TS
authors.lastname: Ganesan
authors.forename: J
authors.initials: J
authors.lastname: Searle
authors.forename: C
authors.initials: C
authors.lastname: Choi
authors.forename: J C
authors.initials: JC
authors.lastname: Barrett
authors.forename: S K
authors.initials: SK
authors.lastname: Khoo
authors.forename: B
authors.initials: B
authors.lastname: Ward
mesh_terms: D002872:Chromosome Deletion; D005260:Female; D011905:Genes, ras; D006579:Heterozygote; D006801:Humans; D009154:Mutation; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000473:pathology; D016019:Survival Analysis